Leonard Mazur - Citius Oncology, CEO Chairman
| CTOR Stock | 0.94 0.06 6.00% |
Chairman
Leonard Mazur is CEO Chairman of Citius Oncology,
| Age | 79 |
| Address | 420 Lexington Avenue, New York, NY, United States, 10170 |
| Phone | 347-627-0058 |
Leonard Mazur Latest Insider Activity
Tracking and analyzing the buying and selling activities of Leonard Mazur against Citius Oncology, stock is an integral part of due diligence when investing in Citius Oncology,. Leonard Mazur insider activity provides valuable insight into whether Citius Oncology, is net buyers or sellers over its current business cycle. Note, Citius Oncology, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Citius Oncology,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Leonard Mazur over a month ago Disposition of 1165048 shares by Leonard Mazur of Citius Pharmaceuticals at 1.42 subject to Rule 16b-3 | ||
Leonard Mazur over two months ago Disposition of 2234700 shares by Leonard Mazur of Citius Pharmaceuticals at 0.77 subject to Rule 16b-3 | ||
Leonard Mazur over three months ago Acquisition by Leonard Mazur of 2234700 shares of Citius Pharmaceuticals at 0.8951 subject to Rule 16b-3 | ||
Leonard Mazur over six months ago Disposition of 1165048 shares by Leonard Mazur of Citius Pharmaceuticals at 1.42 subject to Rule 16b-3 |
Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| Ronald CPA | Prestige Brand Holdings | 60 | |
| Richard Pops | Alkermes Plc | 62 | |
| Sharon Mates | Intracellular Th | 71 | |
| Ruben Minski | Procaps Group SA | 72 | |
| Jack Bendheim | Phibro Animal Health | 77 | |
| Ronald Lombardi | Prestige Brand Holdings | 60 | |
| David Stack | Pacira BioSciences, | 74 | |
Citius Oncology, Leadership Team
Elected by the shareholders, the Citius Oncology,'s board of directors comprises two types of representatives: Citius Oncology, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Citius. The board's role is to monitor Citius Oncology,'s management team and ensure that shareholders' interests are well served. Citius Oncology,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Citius Oncology,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Myron MD, Chief Officer | ||
| Leonard Mazur, CEO Chairman | ||
| Jaime Bartushak, CFO Treasurer | ||
| Myron Holubiak, Secretary Director |
Citius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Citius Oncology, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 116.23 M | ||||
| Shares Outstanding | 2 M | ||||
| Number Of Shares Shorted | 39.42 K | ||||
| Price To Book | 4.55 X | ||||
| Market Capitalization | 116.23 M |
Pair Trading with Citius Oncology,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.8 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.72 | ESPR | Esperion Therapeutics | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.67 | FLGC | Flora Growth Corp | PairCorr |
| 0.6 | NBY | NovaBay Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.